Leaders in Pharmaceutical Business Intelligence (LPBI) Group

PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered

Author: Aviva Lev-Ari, PhD, RN

 

Four Opportunities for PhDs, MDs, MD/PhDs, PharmDs

e-Mail your CV to: avivalev-ari@alum.berkeley.edu

The Process atLPBI Group involves the following steps:

 

#1: Skype interview with Scientist Candidate

• Aviva
• Gerard

#2: Scientist Candidate is invited to present to the Team

• 60 minutes: FIVE Projects completed that yielded a Publication: Abstract and Reference for each project
• 60 minutes: Scientist Candidate present the MAPPING of his set of skills onto the our MAP presented, below in MATERIALS TO BE REVIEWED by Scientist Candidates
• 60 minutes: Group discussion on the above two presentations

#3: Candidate and the Team express interest in collaboration

• Team agree to invite the Scientist Candidate to join the Team
• Candidate e-mail request to receive our Admission Kit

#4: Candidate returns CV in MS Word and the FORM with 12 Declared Categories of Research

#5: We Grant Candidate ACCESS to the platform at “Author” privilege level on pharmaceuticalintelligence.com

#6: Candidate join the Weekly Team meetings on FRIDAYS at

9AM EST=6AM PST = 3PM Swiss Time = 4PM Israel Time

#7: Candidate submit a Project Proposal for funding R&D in CAR-T and TCRL for the Anti-Cancer Indication

#8: NewCo’s Management aggregated all Proposals into a MASTER R&D Plan for NewCo Drug Discovery effort in the three Indications to be performed by a SATELLITE of GLOBAL CANCER RESEARCHERS in their own Lab setting as PIs or in the NewCo facility in Boston, MA

Same process will be defined for the other two indications in the NewCo’s portfolio of Drug development in the Pipeline for 2016/2017.

• Anti-inflammatory

Anti-Inflammatory MATERIALS TO BE REVIEWED by Scientist Candidates [to be added]

• Diabetes

Diabetes MATERIALS TO BE REVIEWED by Scientist Candidates [to be added]

Four Opportunities for PhDs, MDs, MD/PhDs, PharmDs – Scientist Candidate will review the following opportunities withLPBI Group’ Virtual Team

 

• Expert, Author, Writer (EAW) in the Journal 

Open Access Online Scientific Journal

Launched on 4/30/2012

http://pharmaceuticalintelligence.com

Site Statistics on 2/18/2016

Date	Views to Date	# of articles	NIH Clicks	Nature Clicks
6/24/2013	199,857	1,034	1,275	661
7/29/2013	217,356	1,138	1,389	705
12/11/2013	293,694	1,464	1,693	828
10/17/2015	765,762	3,444	2,726	1,683

02/18/2016

886,454

4,162

2,911

1,813

https://pharmaceuticalintelligence.com/

• Potential Co-Editorship on e-Books published on Amazon.com

https://pharmaceuticalintelligence.com/biomed-e-books/

• Potential Author-Narrator on our Audio-Podcast Series in Medicine

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

All opportunities above are on Equity Sharing basis

– EAWs – per number of words published in the Journal,

– e-Book Editors are on 15% Royalties,

– BDs are Riders on my own Finder Fee Agreements in place

• Potential involvement in Drug Discovery on Anti-Cancer – CAR–T and TCRL in a newly under formation Biotech Start up as Scientist I,II,III ot Project R&D Management

https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/anti-cancer-car-t/

Start up will have employment opportunity for Scientist I,II,III and Project R&D Management positions per experience pending Funding secured to finance the Drug Discovery projects for the Three Indication, as above

Anti-Cancer MATERIALS TO BE REVIEWED by Scientist Candidates

For the Anti-Cancer Indication – Scientist Candidates will review the following links:

 

Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

• Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

• Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

• Series C: e-Books on Cancer & Oncology

Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

• Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed
  Reporter: Aviva Lev-Ari, PhD, RN